Description
Arixtra (fondaparinux natrium) 12.5 mg/ml. 0.6 ml. (7.5 mg.) #10
Description:
Arixtra is a medication that contains the active ingredient fondaparinux sodium. Each prefilled syringe contains 12.5 mg/ml. of fondaparinux sodium in a 0.6 ml. solution, which equates to 7.5 mg. of the active ingredient per syringe. Arixtra is available in a pack size of 10 syringes.
Indications:
Arixtra is used to prevent blood clots in patients who are undergoing surgery or have certain medical conditions that increase their risk of developing blood clots. It is commonly used in patients undergoing hip or knee replacement surgery to reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Mechanism of Action:
Fondaparinux sodium, the active ingredient in Arixtra, is a selective inhibitor of factor Xa, an enzyme involved in the blood clotting process. By inhibiting factor Xa, fondaparinux prevents the formation of thrombin, a key enzyme in the blood coagulation cascade. This helps to prevent the formation of blood clots in the veins and arteries.
Dosage and Administration:
Arixtra is administered by subcutaneous injection. The usual dose for the prevention of blood clots in patients undergoing surgery is 2.5 mg. once daily, starting 6 to 8 hours after surgery and continuing for up to 5 to 9 days post-surgery. The exact dose and duration of treatment may vary depending on the patient’s individual risk factors and medical condition. It is important to follow the dosing instructions provided by your healthcare provider.
Contraindications:
Arixtra is contraindicated in patients with a history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). It should not be used in patients with active major bleeding, bacterial endocarditis, severe renal impairment, or known hypersensitivity to fondaparinux sodium or any of the excipients in the formulation.
Side Effects:
Common side effects of Arixtra may include bleeding, bruising, injection site reactions, nausea, and headache. Serious side effects such as severe bleeding, allergic reactions, and thrombocytopenia (low platelet count) may occur rarely. It is important to seek medical attention if you experience any unusual or severe side effects while taking Arixtra.
Precautions and Warnings:
Patients receiving Arixtra should be monitored for signs of bleeding, including unusual bruising, blood in the urine or stool, or prolonged bleeding from cuts. Arixtra should be used with caution in patients with a history of bleeding disorders, gastrointestinal ulcers, or recent surgery. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter and herbal supplements, before starting Arixtra.
Storage:
Arixtra should be stored at room temperature (15-30°C) in its original packaging to protect it from light and moisture. Do not freeze Arixtra, and keep it out of reach of children. Do not use Arixtra if the solution is discolored or contains particles.
Conclusion:
Arixtra is a medication containing fondaparinux sodium, which is used to prevent blood clots in patients at risk of thromboembolic events. It works by inhibiting factor Xa in the blood coagulation cascade, thereby preventing the formation of blood clots. Arixtra is administered by subcutaneous injection and should be used with caution in patients with a history of bleeding disorders or other medical conditions that may increase the risk of bleeding. It is important to follow the dosing instructions provided by your healthcare provider and to report any unusual side effects or complications while taking Arixtra.
